Skip to main content
. Author manuscript; available in PMC: 2018 Nov 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2017 Jul 20;37(11):2102–2113. doi: 10.1161/ATVBAHA.117.309401

Figure 3.

Figure 3

SMC-specific loss of TGF-β signaling—not systemic TGF-β signaling blockade—exacerbates angiotensin II-induced gross thoracic aortic pathology. After 28 days of angiotensin II infusion, aortas were removed from: control mice (no TGF-β inhibition); mice with systemic inhibition of TGF-β activity; and mice with SMC-specific loss of TGF-β signaling. (A) Ascending aortic diameters (adventitia to opposite side of adventitia), measured on images of explanted aortas. Red lines indicate group means; data points are individual mice. (B) Prevalence of thoracic aortic pathology and number of mice affected (shown by sex). (C) Severity of thoracic aortic pathology. (D) Scale for grading thoracic aortic pathology, with examples. (A) P value is from one-way ANOVA; (n=18–21 per group). (B–C) P values are from chi-square tests (n=22–24 per group). (B) Overall P value comparing the 3 groups is above. (E) Ruler is in mm.